Cytek Biosciences Inc. (CTKB)
4.30
-0.19 (-4.23%)
At close: Mar 03, 2025, 3:59 PM
4.30
-0.12%
After-hours: Mar 03, 2025, 04:00 PM EST
No 1D chart data available
| Bid | 4.14 |
| Market Cap | 554.53M |
| Revenue (ttm) | 173.67M |
| Net Income (ttm) | -5.92M |
| EPS (ttm) | -0.05 |
| PE Ratio (ttm) | -86.1 |
| Forward PE | 39.13 |
| Analyst | Buy |
| Ask | 4.46 |
| Volume | 662,523 |
| Avg. Volume (20D) | 726,877 |
| Open | 4.48 |
| Previous Close | 4.49 |
| Day's Range | 4.30 - 4.57 |
| 52-Week Range | 4.22 - 9.33 |
| Beta | 1.40 |
About CTKB
Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system, which leverages full sp...
Industry Medical - Devices
Sector Healthcare
IPO Date Jul 23, 2021
Employees 645
Stock Exchange NASDAQ
Ticker Symbol CTKB
Website https://cytekbio.com
Analyst Forecast
According to 1 analyst ratings, the average rating for CTKB stock is "Buy." The 12-month stock price forecast is $8.5, which is an increase of 97.44% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
Earnings Surprise
Cytek Biosciences has released their quartely earnings
on Feb 27, 2025:
Next Earnings Release
Cytek Biosciences Inc. is scheduled to release its earnings on May 7, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
4 days ago
-6.65%
Cytek Biosciences shares are trading lower after t...
Unlock content with
Pro Subscription
3 months ago
+36.03%
Cytek Biosciences shares are trading higher after the company reported better-than-expected Q3 financial results.
